Aileron Therapeutics (NASDAQ: ALRN) has successfully closed a public offering of 10,162,059 shares of common stock, including an additional 1,071,149 shares exercised by underwriters, at a price of $1.10 per share. This offering generated gross proceeds of $11.2 million prior to deductions. The funds will be utilized for the clinical development of ALRN-6924 as a chemoprotective agent and for general corporate purposes. William Blair & Company acted as the sole book-running manager for the offering, which was conducted under an effective registration statement filed with the SEC.
Aileron Therapeutics (NASDAQ: ALRN) has priced an underwritten public offering of 9,090,910 shares at $1.10 per share, raising gross proceeds of $10 million. The offering includes a 30-day option for underwriters to purchase an additional 1,363,636 shares. The net proceeds will be allocated to the clinical development of ALRN-6924 and general corporate purposes. The offering closes on June 8, 2020, subject to customary conditions. The shares are offered under an effective SEC registration statement.
Aileron Therapeutics (NASDAQ: ALRN) has initiated a public offering of its common stock, with a potential 15% overallotment option for underwriters. Proceeds will support the clinical development of ALRN-6924 as a chemoprotective agent and for general corporate purposes. The offering follows an effective shelf registration statement with the SEC. William Blair & Company is the sole manager of the offering, which is subject to market conditions and may vary in size and terms.
Aileron Therapeutics (NASDAQ: ALRN) has expanded the dose optimization segment of its Phase 1b/2 clinical trial for ALRN-6924, aiming to protect small cell lung cancer (SCLC) patients from chemotherapy-induced toxicity. The first patient has been enrolled in an expansion cohort to evaluate a selected dose for chemoprotection against topotecan-related bone marrow toxicities. Aileron anticipates interim results by June 2020 and final data, including from this expansion, by Q4 2020. ALRN-6924 is a first-in-class dual MDM2/MDMX inhibitor targeting SCLC toxicities.